FINDMED (https://findmed.fr), through its series of webinars, introduces you to the expertise and cutting-edge technological platforms of the Carnot Institutes of our consortium, which are accessible to companies in the fields of drugs and health technologies.
During our next webinar, we propose to focus on the innovative technology of protein chips for proteomic analysis, then on the tools for your genomic and transcriptomic projects, and finally on the Living Lab approach that allows actors to be active in the design of innovative health solutions, leading to an adapted and efficient industrial offer.
This webinar will be animated by Vincent Puard, director of the RPPA platform of the Carnot Curie-Cancer and founder of the MabSilico company, Marina Moletta-Denat, business developer INRA-Transfert for the Get platform of GenoToul, Carnot France Futur Elevage, and Romain Gombert, head of the Living Lab cLLAPS of the Carnot ICM.
Analysis of the expression of proteins of interest
Study of the activation of cell signalling pathways and their dynamics
Identification of predictive and prognostic biomarkers
Identification of therapeutic targets and pharmacodynamic studies
From extraction of nucleic acids to final results
Transcriptome and Genotyping Analysis
De novo sequencing and resequencing of eukaryotic or prokaryotic genomes
Bioinformatics and bio-statistical analyses.
Living Lab: a user-centred exchange platform
cLLAPS: development of products and services for health and autonomy
Mobilization of actors to create and validate innovative solutions
Improving the quality of care for the citizen-user-patient
Participation in this webinar is free but subject to registration.
Findmed is a consortium of 10 Carnot institutes, which are French academic research institutions dedicated to setting up collaborative research partnerships with the private sector. industry (from SMEs to international corporations). The objective of Findmed is to facilitate the access of private companies to their expertise and technological resources, so as to contribute to the reinforcement of the medication / drug discovery sector in France.